Literature DB >> 22104733

New vistas in opioid control of pain.

Hirokazu Mizoguchi1, Chizuko Watanabe, Tsukasa Sakurada, Shinobu Sakurada.   

Abstract

The μ-opioid receptors mainly contribute to the control of pain transmission, while a number of splice variants may have different physiological roles. In fact, some μ-opioid receptor agonists show distinct antinociceptive properties probably mediated via splice variants insensitive to traditional μ-opioid receptor agonists. These atypical μ-opioid receptor agonists are extremely effective against morphine-resistant interactive pain and lack the psychological dependence liability. μ-Opioid receptor splice variants specific for these atypical agonists may be the target for better analgesics effective against morphine-resistant interactive pain and lacking psychological dependence liability. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22104733     DOI: 10.1016/j.coph.2011.10.020

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  4 in total

1.  New trends in pain research: from basic research to clinical translation.

Authors:  Laura Berliocchi; Maria Maiarù; Damiana Scuteri; Maria Tiziana Corasaniti; Giacinto Bagetta
Journal:  Funct Neurol       Date:  2012 Oct-Dec

Review 2.  Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1).

Authors:  Alisa Knapman; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

3.  β-Arrestin 2 and ERK1/2 Are Important Mediators Engaged in Close Cooperation between TRPV1 and µ-Opioid Receptors in the Plasma Membrane.

Authors:  Barbora Melkes; Vendula Markova; Lucie Hejnova; Jiri Novotny
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

Review 4.  The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential.

Authors:  Gerald W Zamponi; Joerg Striessnig; Alexandra Koschak; Annette C Dolphin
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.